HealthEquity is in a sustained uptrend, with the stock up 27.0% over the past year and currently trading at $94.64, which is 89.3% of its 52-week range ($72.76–$105.96). This positioning near the upper end of the range suggests strong bullish momentum, though it also implies the stock may be approaching overbought territory. The 52-week high of $105.96 represents a key resistance level, while the low of $72.76 serves as a support floor. Short-term momentum is accelerating sharply: the stock gained 11.3% in the last month and 14.8% over the past three months, significantly outpacing the S&P 500's 0.78% and 3.5% returns over the same periods. This divergence indicates strong relative strength, with the 1-month relative strength of +10.6% confirming that HealthEquity is a market leader. The recent price action shows a breakout from a consolidation range between $80 and $90 in late June, with the stock surging from $88.46 on June 26 to $94.64 by July 24, a gain of 7.0% in less than a month. The stock's beta of 0.21 is remarkably low, meaning it is significantly less volatile than the market—a 1% move in the S&P 500 historically corresponds to only a 0.21% move in HealthEquity. This low beta, combined with the strong uptrend, suggests the stock offers a favorable risk-reward profile for momentum investors, though the low volatility also implies that breakouts may be less explosive. Key support lies at the 52-week low of $72.76, while resistance is at the 52-week high of $105.96. A breakout above $105.96 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below $72.76 would negate the bullish structure and suggest a potential trend reversal.

HealthEquity's revenue trajectory is solidly growing, with the most recent quarter (Q1 FY2027, ended April 30, 2026) reporting revenue of $354.6 million, a 7.2% increase year-over-year. This growth is driven by a mix of service revenue ($122.9 million), financial service revenue ($174.3 million), and credit/debit card fees ($57.4 million), with the financial service segment benefiting from higher interest income on HSA cash balances. The multi-quarter trend shows accelerating growth: revenue has risen from $300.4 million in Q3 FY2025 to $334.6 million in Q4 FY2026 and now $354.6 million, indicating a clear upward trajectory. The company is highly profitable, with net income of $69.4 million in the latest quarter, up from $53.9 million in the year-ago period, representing a 28.7% increase. Gross margin expanded to 72.3% in Q1 FY2027 from 59.6% in Q1 FY2026, driven by a favorable mix shift toward higher-margin service and financial revenue. Operating margin improved to 29.0% from 25.5% a year ago, reflecting strong operating leverage as the company scales. Net margin reached 19.6%, up from 16.3% in the prior-year quarter, demonstrating that profitability is expanding alongside revenue growth. HealthEquity maintains a fortress balance sheet with a current ratio of 3.27 and a debt-to-equity ratio of just 0.48, indicating low financial leverage and ample liquidity. Free cash flow (FCF) was $97.2 million in the latest quarter, bringing trailing twelve-month FCF to $487.6 million, which represents a FCF yield of approximately 6.6% based on the current market cap of $7.38 billion. The company generated $97.5 million in operating cash flow in Q1, easily covering capital expenditures of only $0.4 million, underscoring the asset-light nature of the business. Return on equity (ROE) stands at 10.2%, while return on assets (ROA) is 6.5%, both healthy levels that indicate efficient capital allocation.